赛升药业拟择机出售所持绿竹生物、康乐卫士股票

Core Viewpoint - The company plans to enhance asset structure and operational efficiency by proposing to the board to authorize management to sell shares of Green Bamboo Biotechnology and Kang Le Wei Shi based on market conditions [1] Summary by Sections - Company Holdings - The company currently holds 13.7515 million shares of Green Bamboo Biotechnology, accounting for 6.79% of its total share capital [1] - The company holds 1.364 million shares of Kang Le Wei Shi, representing 0.4855% of its total share capital [1]